Figure 2.
IDH mutation (ie, IDH1 R132, IDH2 R140, IDH2 R172) frequency, CIR, EFS, and OS of HSCT-consolidated patients with AML according to the ELN2017 risk groups. (A) ELN2017 favorable, (B) ELN2017 intermediate, and (C) ELN2017 adverse.
IDH mutation (ie, IDH1 R132, IDH2 R140, IDH2 R172) frequency, CIR, EFS, and OS of HSCT-consolidated patients with AML according to the ELN2017 risk groups. (A) ELN2017 favorable, (B) ELN2017 intermediate, and (C) ELN2017 adverse.
